The firm on a call with analysts raised its 2026 full-year revenue guidance, citing growth in new products, including ...
The FDA earlier this month accepted the firm's biological license application for DYNE-251 for the treatment of Duchenne muscular dystrophy.
The partners will conduct preclinical studies to select a lead antisense oligonucleotide candidate therapy for testing in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results